How do you hurt us? Let me count the ways: Assobiotec's Palmisano's lament
This article was originally published in Scrip
Italy is preparing to sign off swingeing new measures to contain drug spending as part of a broad Spending Review, while its Health Ministry is calling for measures that could allow unapproved medicines access to the market if they offer a significant discount to medicines on the market for the same indication (scripintelligence.com, 26 July 2012). Riccardo Palmisano, executive vice-president of the biotechnology association Assobiotec, talked to Scrip's Eleanor Malone about the threats to industry and his fears and frustrations in this regard.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.